---
title: "Beijing's first pilot variety approved, rare disease innovative drug \"cross-border segmented production\" launched globally simultaneously"
description: "Recently, the cross-border segmented production pilot of Nicarbazin injection by Johnson & Johnson Pharmaceutical Ltd. was approved by the National Medical Products Administration. This is an innovati"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/241143876.md"
published_at: "2025-05-21T03:07:31.000Z"
---

# Beijing's first pilot variety approved, rare disease innovative drug "cross-border segmented production" launched globally simultaneously

> Recently, the cross-border segmented production pilot of Nicarbazin injection by Johnson & Johnson Pharmaceutical Ltd. was approved by the National Medical Products Administration. This is an innovative product launched simultaneously worldwide and is the first biological product in the country for the treatment of the rare disease "generalized myasthenia gravis" in adolescents aged 12 and above and adult patients. According to the Municipal Medical Products Administration, the raw liquid of this product is produced domestically, while the formulation and packaging are produced overseas, making it the first approved segmented production pilot for biological products in the city

Recently, Johnson & Johnson's Nicarbazin injection cross-border segmented production pilot has been approved by the National Medical Products Administration. This is an innovative product launched simultaneously worldwide and is the first biological product in the country for treating the rare disease "generalized myasthenia gravis" in adolescents aged 12 and older and adult patients. According to the city's drug regulatory bureau, the raw liquid of this product is produced domestically, while the formulation and packaging are produced overseas, making it the first approved segmented production pilot for biological products in this city

### Related Stocks

- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Johnson & Johnson rises on planned $1 billion investment in Pennslyvania | Shares of Johnson & Johnson (JNJ) rose 0.3% to $244.40 following the announcement of a planned investment exceeding $1 b | [Link](https://longbridge.com/en/news/276261089.md) |
| Could This Single Dividend King Make Your Portfolio Worth $1 Million in 20 Years? | Johnson & Johnson (JNJ) is a leading healthcare company known for its 62 consecutive years of dividend increases. Despit | [Link](https://longbridge.com/en/news/259050773.md) |
| PNC Financial Services Group Inc. Acquires 3,223 Shares of Alibaba Group Holding Limited $BABA | PNC Financial Services Group Inc. increased its stake in Alibaba Group Holding Limited by 7.1% in Q3, acquiring an addit | [Link](https://longbridge.com/en/news/276318339.md) |
| SolarEdge Technologies Q4 Earnings Report: What Investors Need to Know | SolarEdge Technologies (NASDAQ:SEDG) reported Q4 earnings on February 18, 2026, beating estimates by 64.1% with an EPS o | [Link](https://longbridge.com/en/news/276229789.md) |
| Canada's Teck Resources beats Q4 revenue, EPS estimates | Teck Resources reported Q4 revenue and adjusted EPS that exceeded analyst expectations, driven by higher copper prices a | [Link](https://longbridge.com/en/news/276305342.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.